Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 60 entries
Sorted by: Best Match Show Resources per page
Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway.

Forum on immunopathological diseases and therapeutics

Lee J, Ahn E, Kissick HT, Ahmed R.
PMID: 28286692
For Immunopathol Dis Therap. 2015;6(1):7-17. doi: 10.1615/ForumImmunDisTher.2015014188.

T-cell exhaustion due to persistent antigen stimulation is a key feature of chronic viral infections and cancer. Programmed cell death-1 (PD-1) is a major regulator of T-cell exhaustion, and blocking the PD-1 pathway restores T-cell function and improves pathogen...

Cite
Lee J, Ahn E, Kissick HT, et al. Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. For Immunopathol Dis Therap. 2015;6(1):7-17doi: 10.1615/ForumImmunDisTher.2015014188.
Lee, J., Ahn, E., Kissick, H. T., & Ahmed, R. (2015). Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. Forum on immunopathological diseases and therapeutics, 6(1), 7-17. https://doi.org/10.1615/ForumImmunDisTher.2015014188
Lee, Junghwa, et al. "Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway." Forum on immunopathological diseases and therapeutics vol. 6,1 (2015): 7-17. doi: https://doi.org/10.1615/ForumImmunDisTher.2015014188
Lee J, Ahn E, Kissick HT, Ahmed R. Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. For Immunopathol Dis Therap. 2015;6(1):7-17. doi: 10.1615/ForumImmunDisTher.2015014188. PMID: 28286692; PMCID: PMC5341794.
Copy Download .nbib Format: NLM
New developments in the biology and the treatment of metastatic Merkel cell carcinoma.

Current opinion in oncology

Terheyden P, Becker JC.
PMID: 28282342
Curr Opin Oncol. 2017 May;29(3):221-226. doi: 10.1097/CCO.0000000000000363.

PURPOSE OF REVIEW: Patients with stage IIIB und IV metastatic Merkel cell carcinoma (mMCC), who are not suitable candidates for surgery or radiotherapy, are unlikely to achieve lasting remission or tumor control by chemo or targeted therapy. In the...

Cite
Terheyden P, Becker JC. New developments in the biology and the treatment of metastatic Merkel cell carcinoma. Curr Opin Oncol. 2017;29(3):221-226doi: 10.1097/CCO.0000000000000363.
Terheyden, P., & Becker, J. C. (2017). New developments in the biology and the treatment of metastatic Merkel cell carcinoma. Current opinion in oncology, 29(3), 221-226. https://doi.org/10.1097/CCO.0000000000000363
Terheyden, Patrick, and Becker, Jürgen C. "New developments in the biology and the treatment of metastatic Merkel cell carcinoma." Current opinion in oncology vol. 29,3 (2017): 221-226. doi: https://doi.org/10.1097/CCO.0000000000000363
Terheyden P, Becker JC. New developments in the biology and the treatment of metastatic Merkel cell carcinoma. Curr Opin Oncol. 2017 May;29(3):221-226. doi: 10.1097/CCO.0000000000000363. PMID: 28282342.
Copy Download .nbib Format: NLM
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.

Endocrine connections

Jaafar J, Fernandez E, Alwan H, Philippe J.
PMID: 29739808
Endocr Connect. 2018 May;7(5):R196-R211. doi: 10.1530/EC-18-0079.

BACKGROUND: Monoclonal antibodies blocking the programmed cell death-1 (PD-1) or its ligand (PD-L1) are a group of immune checkpoints inhibitors (ICIs) with proven antitumor efficacy. However, their use is complicated by immune-related adverse events (irAEs), including endocrine adverse events...

Cite
Jaafar J, Fernandez E, Alwan H, et al. Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocr Connect. 2018;7(5):R196-R211doi: 10.1530/EC-18-0079.
Jaafar, J., Fernandez, E., Alwan, H., & Philippe, J. (2018). Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocrine connections, 7(5), R196-R211. https://doi.org/10.1530/EC-18-0079
Jaafar, Jaafar, et al. "Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism." Endocrine connections vol. 7,5 (2018): R196-R211. doi: https://doi.org/10.1530/EC-18-0079
Jaafar J, Fernandez E, Alwan H, Philippe J. Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocr Connect. 2018 May;7(5):R196-R211. doi: 10.1530/EC-18-0079. PMID: 29739808; PMCID: PMC5937198.
Copy Download .nbib Format: NLM
Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.

Journal of hepatology

Carpino G, Cardinale V, Di Giamberardino A, Overi D, Donsante S, Colasanti T, Amato G, Mennini G, Franchitto M, Conti F, Rossi M, Riminucci M, Gaudio E, Alvaro D, Mancone C.
PMID: 34329660
J Hepatol. 2021 Dec;75(6):1377-1386. doi: 10.1016/j.jhep.2021.07.016. Epub 2021 Jul 28.

BACKGROUND & AIMS: The microenvironment of intrahepatic cholangiocarcinoma (iCCA) is hypovascularized, with an extensive lymphatic network. This leads to rapid cancer spread into regional lymph nodes and the liver parenchyma, precluding curative treatments. Herein, we investigated which factors released...

Cite
Carpino G, Cardinale V, Di Giamberardino A, et al. Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma. J Hepatol. 2021;75(6):1377-1386doi: 10.1016/j.jhep.2021.07.016.
Carpino, G., Cardinale, V., Di Giamberardino, A., Overi, D., Donsante, S., Colasanti, T., Amato, G., Mennini, G., Franchitto, M., Conti, F., Rossi, M., Riminucci, M., Gaudio, E., Alvaro, D., & Mancone, C. (2021). Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma. Journal of hepatology, 75(6), 1377-1386. https://doi.org/10.1016/j.jhep.2021.07.016
Carpino, Guido, et al. "Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma." Journal of hepatology vol. 75,6 (2021): 1377-1386. doi: https://doi.org/10.1016/j.jhep.2021.07.016
Carpino G, Cardinale V, Di Giamberardino A, Overi D, Donsante S, Colasanti T, Amato G, Mennini G, Franchitto M, Conti F, Rossi M, Riminucci M, Gaudio E, Alvaro D, Mancone C. Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma. J Hepatol. 2021 Dec;75(6):1377-1386. doi: 10.1016/j.jhep.2021.07.016. Epub 2021 Jul 28. PMID: 34329660.
Copy Download .nbib Format: NLM
Resistance mechanisms to checkpoint inhibitors.

Current opinion in immunology

Weiss SA, Sznol M.
PMID: 33676271
Curr Opin Immunol. 2021 Apr;69:47-55. doi: 10.1016/j.coi.2021.02.001. Epub 2021 Mar 03.

Although multiple immune checkpoint inhibitors (ICI) have been identified and tested in the clinic, antibodies blocking the PD-1/PD-L1 axis have produced the greatest impact on cancer treatment. Many potential mechanisms of treatment failure have been proposed from pre-clinical animal...

Cite
Weiss SA, Sznol M. Resistance mechanisms to checkpoint inhibitors. Curr Opin Immunol. 2021;69:47-55doi: 10.1016/j.coi.2021.02.001.
Weiss, S. A., & Sznol, M. (2021). Resistance mechanisms to checkpoint inhibitors. Current opinion in immunology, 6947-55. https://doi.org/10.1016/j.coi.2021.02.001
Weiss, Sarah A, and Sznol, Mario. "Resistance mechanisms to checkpoint inhibitors." Current opinion in immunology vol. 69 (2021): 47-55. doi: https://doi.org/10.1016/j.coi.2021.02.001
Weiss SA, Sznol M. Resistance mechanisms to checkpoint inhibitors. Curr Opin Immunol. 2021 Apr;69:47-55. doi: 10.1016/j.coi.2021.02.001. Epub 2021 Mar 03. PMID: 33676271.
Copy Download .nbib Format: NLM
Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy.

Biomaterials

Yu Y, Li J, Song B, Ma Z, Zhang Y, Sun H, Wei X, Bai Y, Lu X, Zhang P, Zhang X.
PMID: 34896861
Biomaterials. 2021 Dec 06;280:121312. doi: 10.1016/j.biomaterials.2021.121312. Epub 2021 Dec 06.

Checkpoint inhibitors, such as antibodies blocking the PD-1/PD-L1 pathway, are among the most promising immunotherapies to treat metastatic cancers, but their response rate remains low. In addition, the usage of monoclonal antibodies as checkpoint inhibitors is associated with a...

Cite
Yu Y, Li J, Song B, et al. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2021;280:121312doi: 10.1016/j.biomaterials.2021.121312.
Yu, Y., Li, J., Song, B., Ma, Z., Zhang, Y., Sun, H., Wei, X., Bai, Y., Lu, X., Zhang, P., & Zhang, X. (2021). Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials, 280121312. https://doi.org/10.1016/j.biomaterials.2021.121312
Yu, Yunjian, et al. "Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy." Biomaterials vol. 280 (2021): 121312. doi: https://doi.org/10.1016/j.biomaterials.2021.121312
Yu Y, Li J, Song B, Ma Z, Zhang Y, Sun H, Wei X, Bai Y, Lu X, Zhang P, Zhang X. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2021 Dec 06;280:121312. doi: 10.1016/j.biomaterials.2021.121312. Epub 2021 Dec 06. PMID: 34896861.
Copy Download .nbib Format: NLM
Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy.

Biomaterials

Yu Y, Li J, Song B, Ma Z, Zhang Y, Sun H, Wei X, Bai Y, Lu X, Zhang P, Zhang X.
PMID: 34896861
Biomaterials. 2021 Dec 06;280:121312. doi: 10.1016/j.biomaterials.2021.121312. Epub 2021 Dec 06.

Checkpoint inhibitors, such as antibodies blocking the PD-1/PD-L1 pathway, are among the most promising immunotherapies to treat metastatic cancers, but their response rate remains low. In addition, the usage of monoclonal antibodies as checkpoint inhibitors is associated with a...

Cite
Yu Y, Li J, Song B, et al. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2021;280:121312doi: 10.1016/j.biomaterials.2021.121312.
Yu, Y., Li, J., Song, B., Ma, Z., Zhang, Y., Sun, H., Wei, X., Bai, Y., Lu, X., Zhang, P., & Zhang, X. (2021). Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials, 280121312. https://doi.org/10.1016/j.biomaterials.2021.121312
Yu, Yunjian, et al. "Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy." Biomaterials vol. 280 (2021): 121312. doi: https://doi.org/10.1016/j.biomaterials.2021.121312
Yu Y, Li J, Song B, Ma Z, Zhang Y, Sun H, Wei X, Bai Y, Lu X, Zhang P, Zhang X. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2021 Dec 06;280:121312. doi: 10.1016/j.biomaterials.2021.121312. Epub 2021 Dec 06. PMID: 34896861.
Copy Download .nbib Format: NLM
Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy.

Biomaterials

Yu Y, Li J, Song B, Ma Z, Zhang Y, Sun H, Wei X, Bai Y, Lu X, Zhang P, Zhang X.
PMID: 34896861
Biomaterials. 2021 Dec 06;280:121312. doi: 10.1016/j.biomaterials.2021.121312. Epub 2021 Dec 06.

Checkpoint inhibitors, such as antibodies blocking the PD-1/PD-L1 pathway, are among the most promising immunotherapies to treat metastatic cancers, but their response rate remains low. In addition, the usage of monoclonal antibodies as checkpoint inhibitors is associated with a...

Cite
Yu Y, Li J, Song B, et al. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2021;280:121312doi: 10.1016/j.biomaterials.2021.121312.
Yu, Y., Li, J., Song, B., Ma, Z., Zhang, Y., Sun, H., Wei, X., Bai, Y., Lu, X., Zhang, P., & Zhang, X. (2021). Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials, 280121312. https://doi.org/10.1016/j.biomaterials.2021.121312
Yu, Yunjian, et al. "Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy." Biomaterials vol. 280 (2021): 121312. doi: https://doi.org/10.1016/j.biomaterials.2021.121312
Yu Y, Li J, Song B, Ma Z, Zhang Y, Sun H, Wei X, Bai Y, Lu X, Zhang P, Zhang X. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2021 Dec 06;280:121312. doi: 10.1016/j.biomaterials.2021.121312. Epub 2021 Dec 06. PMID: 34896861.
Copy Download .nbib Format: NLM
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy.

Journal of clinical medicine

Tunger A, Sommer U, Wehner R, Kubasch AS, Grimm MO, Bachmann MP, Platzbecker U, Bornhäuser M, Baretton G, Schmitz M.
PMID: 31557787
J Clin Med. 2019 Sep 25;8(10). doi: 10.3390/jcm8101534.

The administration of antibodies blocking the immune checkpoint molecules programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) has evolved as a very promising treatment option for cancer patients. PD-1/PD-L1 inhibition has significantly enhanced...

Cite
Tunger A, Sommer U, Wehner R, et al. The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. J Clin Med. 2019;8(10)doi: 10.3390/jcm8101534.
Tunger, A., Sommer, U., Wehner, R., Kubasch, A. S., Grimm, M. O., Bachmann, M. P., Platzbecker, U., Bornhäuser, M., Baretton, G., & Schmitz, M. (2019). The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. Journal of clinical medicine, 8(10), . https://doi.org/10.3390/jcm8101534
Tunger, Antje, et al. "The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy." Journal of clinical medicine vol. 8,10 (2019). doi: https://doi.org/10.3390/jcm8101534
Tunger A, Sommer U, Wehner R, Kubasch AS, Grimm MO, Bachmann MP, Platzbecker U, Bornhäuser M, Baretton G, Schmitz M. The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. J Clin Med. 2019 Sep 25;8(10). doi: 10.3390/jcm8101534. PMID: 31557787; PMCID: PMC6832659.
Copy Download .nbib Format: NLM
Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy.

Biomaterials

Yu Y, Li J, Song B, Ma Z, Zhang Y, Sun H, Wei X, Bai Y, Lu X, Zhang P, Zhang X.
PMID: 34896861
Biomaterials. 2021 Dec 06;280:121312. doi: 10.1016/j.biomaterials.2021.121312. Epub 2021 Dec 06.

Checkpoint inhibitors, such as antibodies blocking the PD-1/PD-L1 pathway, are among the most promising immunotherapies to treat metastatic cancers, but their response rate remains low. In addition, the usage of monoclonal antibodies as checkpoint inhibitors is associated with a...

Cite
Yu Y, Li J, Song B, et al. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2021;280:121312doi: 10.1016/j.biomaterials.2021.121312.
Yu, Y., Li, J., Song, B., Ma, Z., Zhang, Y., Sun, H., Wei, X., Bai, Y., Lu, X., Zhang, P., & Zhang, X. (2021). Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials, 280121312. https://doi.org/10.1016/j.biomaterials.2021.121312
Yu, Yunjian, et al. "Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy." Biomaterials vol. 280 (2021): 121312. doi: https://doi.org/10.1016/j.biomaterials.2021.121312
Yu Y, Li J, Song B, Ma Z, Zhang Y, Sun H, Wei X, Bai Y, Lu X, Zhang P, Zhang X. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2021 Dec 06;280:121312. doi: 10.1016/j.biomaterials.2021.121312. Epub 2021 Dec 06. PMID: 34896861.
Copy Download .nbib Format: NLM
Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy.

Biomaterials

Yu Y, Li J, Song B, Ma Z, Zhang Y, Sun H, Wei X, Bai Y, Lu X, Zhang P, Zhang X.
PMID: 34896861
Biomaterials. 2021 Dec 06;280:121312. doi: 10.1016/j.biomaterials.2021.121312. Epub 2021 Dec 06.

Checkpoint inhibitors, such as antibodies blocking the PD-1/PD-L1 pathway, are among the most promising immunotherapies to treat metastatic cancers, but their response rate remains low. In addition, the usage of monoclonal antibodies as checkpoint inhibitors is associated with a...

Cite
Yu Y, Li J, Song B, et al. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2021;280:121312doi: 10.1016/j.biomaterials.2021.121312.
Yu, Y., Li, J., Song, B., Ma, Z., Zhang, Y., Sun, H., Wei, X., Bai, Y., Lu, X., Zhang, P., & Zhang, X. (2021). Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials, 280121312. https://doi.org/10.1016/j.biomaterials.2021.121312
Yu, Yunjian, et al. "Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy." Biomaterials vol. 280 (2021): 121312. doi: https://doi.org/10.1016/j.biomaterials.2021.121312
Yu Y, Li J, Song B, Ma Z, Zhang Y, Sun H, Wei X, Bai Y, Lu X, Zhang P, Zhang X. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2021 Dec 06;280:121312. doi: 10.1016/j.biomaterials.2021.121312. Epub 2021 Dec 06. PMID: 34896861.
Copy Download .nbib Format: NLM
Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy.

Biomaterials

Yu Y, Li J, Song B, Ma Z, Zhang Y, Sun H, Wei X, Bai Y, Lu X, Zhang P, Zhang X.
PMID: 34896861
Biomaterials. 2021 Dec 06;280:121312. doi: 10.1016/j.biomaterials.2021.121312. Epub 2021 Dec 06.

Checkpoint inhibitors, such as antibodies blocking the PD-1/PD-L1 pathway, are among the most promising immunotherapies to treat metastatic cancers, but their response rate remains low. In addition, the usage of monoclonal antibodies as checkpoint inhibitors is associated with a...

Cite
Yu Y, Li J, Song B, et al. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2021;280:121312doi: 10.1016/j.biomaterials.2021.121312.
Yu, Y., Li, J., Song, B., Ma, Z., Zhang, Y., Sun, H., Wei, X., Bai, Y., Lu, X., Zhang, P., & Zhang, X. (2021). Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials, 280121312. https://doi.org/10.1016/j.biomaterials.2021.121312
Yu, Yunjian, et al. "Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy." Biomaterials vol. 280 (2021): 121312. doi: https://doi.org/10.1016/j.biomaterials.2021.121312
Yu Y, Li J, Song B, Ma Z, Zhang Y, Sun H, Wei X, Bai Y, Lu X, Zhang P, Zhang X. Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials. 2021 Dec 06;280:121312. doi: 10.1016/j.biomaterials.2021.121312. Epub 2021 Dec 06. PMID: 34896861.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 60 entries